Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma

Grenier, Karl; Rivière, Jean‐Baptiste; Bencheikh, Bouchra Ouled Amar; Gomez, Andrea; Shieh, B.; Wang, Hangjun; Fiset, Pierre; Camilleri-Broët, Sophie

doi:10.1016/j.jtocrr.2023.100530

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an expression study of human cancer cell lines, ROS1 was found highly expressed in many glioblastoma cell lines but was not seen in normal healthy brain tissue [68]. ROS1 has also been found to be overexpressed in oral carcinoma [69] and lung cancer tissue [70,71]. From the cell line SW-1088, ROS1 was further characterized to encode a 259 kDa (2347 aa) protein with a glycosylated extracellular domain, a single transmembrane domain, and an intracellular tyrosine kinase domain [72].…”

Section: Analysis Of Cd74 Fusion Partnersmentioning

confidence: 99%

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

Vargas,

Pantouris

2023

IJMS

View full text Add to dashboard Cite

CD74 is a type II cell surface receptor found to be highly expressed in several hematological and solid cancers, due to its ability to activate pathways associated with tumor cell survival and proliferation. Over the past 16 years, CD74 has emerged as a commonly detected fusion partner in multiple oncogenic fusion proteins. Studies have found CD74 fusion proteins in a range of cancers, including lung adenocarcinoma, inflammatory breast cancer, and pediatric acute lymphoblastic leukemia. To date, there are five known CD74 fusion proteins, CD74-ROS1, CD74-NTRK1, CD74-NRG1, CD74-NRG2α, and CD74-PDGFRB, with a total of 16 different variants, each with unique genetic signatures. Importantly, the occurrence of CD74 in the formation of fusion proteins has not been well explored despite the fact that ROS1 and NRG1 families utilize CD74 as the primary partner for the formation of oncogenic fusions. Fusion proteins known to be oncogenic drivers, including those of CD74, are typically detected and targeted after standard chemotherapeutic plans fail and the disease relapses. The analysis reported herein provides insights into the early intervention of CD74 fusions and highlights the need for improved routine assessment methods so that targeted therapies can be applied while they are most effective.

show abstract

Section: Analysis Of Cd74 Fusion Partnersmentioning

confidence: 99%

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

Vargas,

Pantouris

2023

IJMS

View full text Add to dashboard Cite

show abstract

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

Vargas,

Pantouris

2023

Preprint

View full text Add to dashboard Cite

CD74 is a type II cell surface receptor found to be highly expressed in several hematological and solid cancers, due to its ability to activate pathways associated with tumor cell survival and proliferation. Over the past 16 years, CD74 is emerging as a commonly detected fusion partner in multiple oncogenic fusion proteins. Studies have found CD74 fusion proteins in a range of cancers including lung adenocarcinoma, inflammatory breast cancer, and pediatric acute lymphoblastic leukemia. To date, there are five known CD74 fusion proteins, CD74-ROS1, CD74-NTRK1, CD74-NRG1, CD74-NRG2a, and CD74-PDGFRB, with a total of 16 different variants, each with unique genetic signatures. Importantly, the occurrence of CD74 in the formation of fusion proteins has not been well explored despite the fact that ROS1 and NRG1 families utilize CD74 as the primary partner for the formation of oncogenic fusions. Fusion proteins known to be oncogenic drivers, including those of CD74, are typically detected, and targeted after standard chemotherapeutic plans fail and the disease relapses. The analysis reported herein provides insights into early intervention of CD74 fusions and highlight the need for improved routine assessment methods so that targeted therapies can be applied while they are most effective.

show abstract

Routine Clinically Detected Increased ROS1 Transcripts Are Related With ROS1 Expression by Immunohistochemistry and Associated With EGFR Mutations in Lung Adenocarcinoma

Cited by 2 publications

References 45 publications

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

Analysis of CD74 Occurrence in Oncogenic Fusion Proteins

Contact Info

Product

Resources

About